Ace the Certified Clinical Transplant Nurse Test 2025 – Transform Your Future with Confidence!

The correct choice is associated with an increased risk of prion disease for a donor exposed to non-recombinant human pituitary-derived growth hormone (hGH). This concern arises because non-recombinant growth hormone was historically derived from human pituitary glands, which poses a potential risk of transmitting prions. Prions are misfolded proteins that can lead to neurodegenerative diseases, such as Creutzfeldt-Jakob disease.

Due to the manner of its production, non-recombinant hGH could potentially contain infectious prions if sourced from donors with certain prion diseases. This specific risk has led to stringent regulations and changes in how growth hormone is produced, favoring recombinant technology, which uses genetically engineered bacteria or yeast to produce hGH, eliminating the risk of prion contamination associated with human-derived materials.

The other options—such as increased risk of influenza, HIV infection, or cancer—are not specifically associated with the use of non-recombinant hGH. For instance, influenza is a viral infection that is not linked to the use of growth hormone, rather it is influenced by factors like vaccination and exposure to the virus. Similarly, while HIV infection poses significant concerns in healthcare and donor settings, the exposure to non-re